Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed symptomatic MM patients who are 65 years of age or younger.
Epistemonikos ID: bd043cdd7acda591d8446f93f35447a37d11258c
First added on: Sep 19, 2017